These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 24778038)

  • 21. Combined medroxyprogesterone acetate/levonorgestrel-intrauterine system treatment in young women with early-stage endometrial cancer.
    Kim MK; Seong SJ; Kim YS; Song T; Kim ML; Yoon BS; Jun HS; Lee YH
    Am J Obstet Gynecol; 2013 Oct; 209(4):358.e1-4. PubMed ID: 23791687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Levonorgestrel-Releasing Intrauterine Systems Versus Oral Cyclic Medroxyprogesterone Acetate in Endometrial Hyperplasia Therapy: A Meta-Analysis.
    Yuk JS; Song JY; Lee JH; Park WI; Ahn HS; Kim HJ
    Ann Surg Oncol; 2017 May; 24(5):1322-1329. PubMed ID: 27896507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Weight variation in users of the levonorgestrel-releasing intrauterine system, of the copper IUD and of medroxyprogesterone acetate in Brazil].
    Yela DA; Monteiro IM; Bahamondes LG; Del Castillo S; Bahamondes MV; Fernandes A
    Rev Assoc Med Bras (1992); 2006; 52(1):32-6. PubMed ID: 16622536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful pregnancy following insertion of a levonorgestrel-releasing intrauterine system in two infertile patients with complex atypical endometrial hyperplasia.
    Qi X; Zhao W; Duan Y; Li Y
    Gynecol Obstet Invest; 2008; 65(4):266-8. PubMed ID: 18196936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention of tamoxifen induced endometrial polyps using a levonorgestrel releasing intrauterine system long-term follow-up of a randomised control trial.
    Gardner FJ; Konje JC; Bell SC; Abrams KR; Brown LJ; Taylor DJ; Habiba M
    Gynecol Oncol; 2009 Sep; 114(3):452-6. PubMed ID: 19576623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of levonorgestrel-releasing intrauterine system in the prevention and treatment of endometrial hyperplasia.
    Ewies AA; Alfhaily F
    Obstet Gynecol Surv; 2012 Nov; 67(11):726-33. PubMed ID: 23151756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficacy of intrauterine versus oral progestin for the treatment of endometrial hyperplasia. A prospective randomized comparative study.
    Dolapcioglu K; Boz A; Baloglu A
    Clin Exp Obstet Gynecol; 2013; 40(1):122-6. PubMed ID: 23724525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Femilis LNG-IUS: contraceptive performance-an interim analysis.
    Wildemeersch D; Janssens D; Andrade A
    Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):103-10. PubMed ID: 19340705
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of endometrial hyperplasia without atypia in peri- and postmenopausal women with a levonorgestrel intrauterine device.
    Haimovich S; Checa MA; Mancebo G; Fusté P; Carreras R
    Menopause; 2008; 15(5):1002-4. PubMed ID: 18451744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of dilatation & curettage and endometrial aspiration biopsy accuracy in patients treated with high-dose oral progestin plus levonorgestrel intrauterine system for early-stage endometrial cancer.
    Kim MK; Seong SJ; Song T; Kim ML; Yoon BS; Jun HS; Lee GH; Lee YH
    Gynecol Oncol; 2013 Sep; 130(3):470-3. PubMed ID: 23822890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The role of copper-releasing intrauterine device or levonorgestrel-releasing intrauterine system on uterine bleeding and iron status (prospective study of 8 years)].
    Imperato F; Perniola G; Mossa B; Marziani R; Perniola F; Stragapede B; Napolitano C
    Minerva Ginecol; 2002 Jun; 54(3):271-8. PubMed ID: 12063443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women.
    Chan SS; Tam WH; Yeo W; Yu MM; Ng DP; Wong AW; Kwan WH; Yuen PM
    BJOG; 2007 Dec; 114(12):1510-5. PubMed ID: 17995495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of Benign Endometrial Polyp Recurrence Using a Levonorgestrel-releasing Intrauterine System in Premenopausal Patients: A Retrospective Cohort Study.
    Wang Y; Yang M; Huang X; Li X; Lin E; Feng Y
    J Minim Invasive Gynecol; 2020; 27(6):1281-1286. PubMed ID: 32446971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential elevation of matrix metalloproteinase expression in women exposed to levonorgestrel-releasing intrauterine system for a short or prolonged period of time.
    Labied S; Galant C; Nisolle M; Ravet S; Munaut C; Marbaix E; Foidart JM; Frankenne F
    Hum Reprod; 2009 Jan; 24(1):113-21. PubMed ID: 18812421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endothelial function in women using levonorgestrel-releasing intrauterine system (LNG-IUS).
    Selim MF; Hussein AF
    Contraception; 2013 Apr; 87(4):396-403. PubMed ID: 23332246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of the levonorgestrel intrauterine system in adolescents with endometriosis.
    Yoost J; LaJoie AS; Hertweck P; Loveless M
    J Pediatr Adolesc Gynecol; 2013 Apr; 26(2):120-4. PubMed ID: 23518190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomised trial comparing the levonorgestrel intrauterine system and thermal balloon ablation for heavy menstrual bleeding.
    Busfield RA; Farquhar CM; Sowter MC; Lethaby A; Sprecher M; Yu Y; Sadler LC; Brown P; Johnson N
    BJOG; 2006 Mar; 113(3):257-63. PubMed ID: 16487195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women.
    Hampton NR; Rees MC; Lowe DG; Rauramo I; Barlow D; Guillebaud J
    Hum Reprod; 2005 Sep; 20(9):2653-60. PubMed ID: 15905289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up.
    Wildemeersch D; Janssens D; Pylyser K; De Wever N; Verbeeck G; Dhont M; Tjalma W
    Maturitas; 2007 Jun; 57(2):210-3. PubMed ID: 17270370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Six months response rate of combined oral medroxyprogesterone/levonorgestrel-intrauterine system for early-stage endometrial cancer in young women: a Korean Gynecologic-Oncology Group Study.
    Kim MK; Seong SJ; Kang SB; Bae DS; Kim JW; Nam JH; Lim MC; Lee TS; Kim S; Paek J
    J Gynecol Oncol; 2019 Mar; 30(2):e47. PubMed ID: 30740964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.